Analytical Data
-
基因名
COVA1
- Application
-
别名
COVA1；COVA1；Ecto-NOX disulfide-thiol exchanger 2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q16206
-
表达区间
1-610aa
-
氨基酸序列
MQRDFRWLWVYEIGYAADNSRTLNVDSTAMTLPMSDPTAWATAMNNLGMAPLGIAGQPILPDFDPALGMMTGIPPITPMMPGLGIVPPPIPPDMPVVKEIIHCKSCTLFPPNPNLPPPATRERPPGCKTVFVGGLPENGTEQIIVEVFEQCGEIIAIRKSKKNFCHIRFAEEYMVDKALYLSGYRIRLGSSTDKKDTGRLHVDFAQARDDLYEWECKQRMLAREERHRRRMEEERLRPPSPPPVVHYSDHECSIVAEKLKDDSKFSEAVQTLLTWIERGEVNRRSANNFYSMIQSANSHVRRLVNEKAAHEKDMEEAKEKFKQALSGILIQFEQIVAVYHSASKQKAWDHFTKAQRKNISVWCKQAEEIRNIHNDELMGIRREEEMEMSDDEIEEMTETKETEESALVSQAEALKEENDSLRWQLDAYRNEVELLKQEQGKVHREDDPNKEQQLKLLQQALQGMQQHLLKVQEEYKKKEAELEKLKDDKLQVEKMLENLKEKESCASRLCASNQDSEYPLEKTMNSSPIKSEREALLVGIISTFLHVHPFGASIEYICSYLHRLDNKICTSDVECLMGRLQHTFKQEMTGVGASLEKRWKFCGFEGLKLT
-
分子量
77.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
COVA1 is a recombinant protein developed in response to the COVID-19 pandemic, aiming to address the urgent need for effective therapeutic options against the SARS-CoV-2 virus. Derived from the spike protein of the virus, COVA1 is designed to neutralize the virus by inhibiting its ability to bind to human ACE2 receptors, thereby preventing infection. The rapid emergence of various SARS-CoV-2 variants highlighted the necessity for vaccines and treatments that could adapt to these changes. Initial studies suggest that COVA1 exhibits a broad neutralizing capability against multiple variants, including those with significant mutations in the spike protein. This characteristic makes it a promising candidate for both therapeutic interventions and potential passive immunization strategies. Research into COVA1 also emphasizes the importance of understanding antibody responses and the mechanisms of viral entry, which are crucial for developing effective countermeasures against current and future coronaviruses. The ongoing exploration into COVA1's efficacy, safety, and production methods not only contributes to the immediate fight against COVID-19 but also enhances preparedness for future pandemics caused by similar viral pathogens. As such, COVA1 research represents a significant advancement in the field of virology and therapeutic development, with implications that extend beyond the current health crisis.
